Relay Therapeutics, Inc.
RLAY
$3.69
$0.288.21%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 8.36M | 7.68M | 10.01M | 10.01M | 35.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.36M | 7.68M | 10.01M | 10.01M | 35.21M |
| Cost of Revenue | 276.33M | 306.85M | 315.44M | 324.88M | 329.75M |
| Gross Profit | -267.97M | -299.17M | -305.43M | -314.87M | -294.55M |
| SG&A Expenses | 72.79M | 79.18M | 80.24M | 80.09M | 78.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 349.12M | 386.03M | 395.68M | 404.96M | 408.57M |
| Operating Income | -340.76M | -378.35M | -385.67M | -394.96M | -373.37M |
| Income Before Tax | -311.55M | -333.39M | -337.71M | -345.20M | -322.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -311.55 | -333.39 | -337.71 | -345.20 | -322.83 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -311.55M | -333.39M | -337.71M | -345.20M | -322.83M |
| EBIT | -340.76M | -378.35M | -385.67M | -394.96M | -373.37M |
| EBITDA | -335.85M | -373.07M | -380.21M | -389.45M | -367.87M |
| EPS Basic | -1.95 | -2.23 | -2.40 | -2.61 | -2.52 |
| Normalized Basic EPS | -1.21 | -1.45 | -1.56 | -1.71 | -1.66 |
| EPS Diluted | -1.95 | -2.23 | -2.40 | -2.61 | -2.52 |
| Normalized Diluted EPS | -1.21 | -1.45 | -1.56 | -1.71 | -1.66 |
| Average Basic Shares Outstanding | 648.06M | 609.62M | 571.23M | 528.65M | 510.65M |
| Average Diluted Shares Outstanding | 648.06M | 609.62M | 571.23M | 528.65M | 510.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |